AdvanDx to Offer BinaxNOW® PBP2a Test for Rapid Detection of PBP2a in Methicillin-Resistant Staphylococcus aureus (MRSA) | SYS-CON MEDIA.
AdvanDx today announced that it will offer the BinaxNOW® PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a (PBP2a) present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures. In clinical studies, the test demonstrated 97.1% positive agreement and 100% negative agreement with conventional methods for detecting MRSA. Early detection of invasive infections due to MRSA is critical in efforts to decrease patient morbidity and mortality, reduce empiric use of vancomycin and permit cost-effective decisions for patient management (2). AdvanDx will offer a unique, cost-effective and easy-to-use solution that will enable laboratories to provide rapid, accurate results 24 hours sooner than with conventional methods.
